구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 3개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | datopotamab deruxtecan (Datroway, DS-1062, Dato-DXd, datopotamab-deruxtecan-dlnk) Daiichi Sankyo / AstraZeneca·TROP2 50 trials·t½ ADC ~6 days; released DXd cleared rapidly | trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201) Daiichi Sankyo / AstraZeneca·HER2 240 trials·t½ ADC ~5.8 days; total antibody ~6.1 days; released DXd ~2.7 days (5.4 mg/kg q3w) | lymphodepleting chemotherapy (lymphodepleting chemotherapy) Hemogenyx Pharmaceuticals LLC·Non-Hodgkin Lymphoma 119 trials |
|---|---|---|---|
Overview Program | Datroway (datopotamab deruxtecan) | Enhertu (trastuzumab deruxtecan) | lymphodepleting chemotherapy |
Overview Company | Daiichi Sankyo / AstraZeneca | Daiichi Sankyo / AstraZeneca | Hemogenyx Pharmaceuticals LLC |
Overview Modality | ADC | ADC | ANTIBODY |
Overview Target | TROP2 | HER2 | Non-Hodgkin Lymphoma |
Overview Indication | HR+/HER2− breast cancer; EGFR-mutated non-small cell lung cancer | HER2+ breast cancer, HER2-low, gastric | Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | ACTIVE |
Overview Content status | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | Same DXd chemistry that made Enhertu work, aimed at TROP2 — high plasma stability with a short-half-life payload to limit systemic exposure. | High DAR (~8), bystander effect, HER2-low activity | — |
Positioning Known limitation | TROP2 loss, SLFN11 status, and topoisomerase I pathway adaptation. | HER2 antigen loss/downregulation, payload efflux, and dose-limiting ILD/pneumonitis leading to discontinuation. | — |
Positioning Development positioning | Second TROP2 ADC to market; competes with Trodelvy on tolerability rather than novelty of target. | Leading efficacy in HER2 ADC class | — |
Technology Payload | DXd (exatecan derivative, topoisomerase I inhibitor) | DXd (topo-I inhibitor) | — |
Technology Linker | Tetrapeptide-based cleavable maleimide linker, DAR ~4 | Cleavable tetrapeptide | — |
Technology DAR | DAR 4 | — | — |
MoA Mechanism | Anti-TROP2 antibody delivers DXd intracellularly after lysosomal linker cleavage; topoisomerase I inhibition drives DNA damage, with membrane-permeable payload producing a bystander effect. | Fam-trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate: humanized anti-HER2 IgG1 linked via a cleavable tetrapeptide linker to DXd, a membrane-permeable topoisomerase I inhibitor. After binding HER2 on tumor cells, the conjugate is internalized; lysosomal proteases cleave the linker and release DXd, causing DNA damage and apoptosis. Released DXd can exert a bystander effect in neighboring cells. | CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia |
MoA Biomarker | TROP2 expression is not a required companion diagnostic; quantitative continuous scoring (QCS) is investigational. | HER2 expression (IHC/ISH per indication); higher systemic exposure associated with greater ILD incidence (FDA label §12.2). | biomarkers exist to predict toxicity risk, underscoring the need for further research |
PK/PD Half-life | ADC ~6 days; released DXd cleared rapidly | ADC ~5.8 days; total antibody ~6.1 days; released DXd ~2.7 days (5.4 mg/kg q3w) | — |
PK/PD Species | Cynomolgus monkey, Mouse, PFS by BICR, ctDNA and TROP2 QCS exploratory | Minipig, Pig, Human, Tumor response (ORR, PFS), ILD incidence rises with exposure | Mouse |
PK/PD Animal (cat.) | Human, Mouse, NHP, In vitro | Human, In vitro | Human, Mouse |
PK/PD Experiment | pd | Pharmacokinetic | Pd |
PK/PD Biodistribution | — | Systemic exposure with tumor-selective HER2-mediated uptake | — |
Toxicology Species | Mouse, Rat, Hamster | Cynomolgus monkey, NHP, Rat, Minipig, Pig, Hamster, Human | Mouse |
Toxicology Animal (cat.) | — | NHP | Human, Mouse |
Toxicology Major finding | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. | ILD-like lung findings at high exposure | thrombocytopenia) but achieved a best response of morphologic leukemia-free state on day 14 foll |
Toxicology CRS | N/A | Minimal | Reported |
Toxicology NOAEL | — | 10 mg/kg | — |
Clinical Safety signal | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. | ILD-like lung findings at high exposure | thrombocytopenia) but achieved a best response of morphologic leukemia-free state on day 14 foll |
Clinical Selected reported efficacy | ORR 79% | ORR 79.7% | ORR 43.8% |
Clinical Reported ORR | 74% | 79.7% | 43.8% |
Clinical Reported PFS | 4.4 | NA | — |
Clinical Reported OS | 12.9 | NA | — |
Clinical Result source | ClinicalTrials.gov NCT04656652 | ClinicalTrials.gov NCT03529110 | ClinicalTrials.gov NCT02445248 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT04656652 | NCT03529110 | NCT02445248 |
Preclinical Animal (cat.) | Mouse, In vitro | Human, Mouse, In vitro | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 3개 · 임상 갱신 필요 1개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | datopotamab deruxtecan (Datroway, DS-1062, Dato-DXd, datopotamab-deruxtecan-dlnk) Daiichi Sankyo / AstraZeneca·TROP2 50 trials·t½ ADC ~6 days; released DXd cleared rapidly | trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201) Daiichi Sankyo / AstraZeneca·HER2 240 trials·t½ ADC ~5.8 days; total antibody ~6.1 days; released DXd ~2.7 days (5.4 mg/kg q3w) | lymphodepleting chemotherapy (lymphodepleting chemotherapy) Hemogenyx Pharmaceuticals LLC·Non-Hodgkin Lymphoma 119 trials |
|---|---|---|---|
Overview Program | Datroway (datopotamab deruxtecan) | Enhertu (trastuzumab deruxtecan) | lymphodepleting chemotherapy |
Overview Company | Daiichi Sankyo / AstraZeneca | Daiichi Sankyo / AstraZeneca | Hemogenyx Pharmaceuticals LLC |
Overview Modality | ADC | ADC | ANTIBODY |
Overview Target | TROP2 | HER2 | Non-Hodgkin Lymphoma |
Overview Indication | HR+/HER2− breast cancer; EGFR-mutated non-small cell lung cancer | HER2+ breast cancer, HER2-low, gastric | Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | ACTIVE |
Overview Content status | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Data Confidence · High | Data Confidence · High | Data Confidence · Low |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | Same DXd chemistry that made Enhertu work, aimed at TROP2 — high plasma stability with a short-half-life payload to limit systemic exposure. | High DAR (~8), bystander effect, HER2-low activity | — |
Positioning Known limitation | TROP2 loss, SLFN11 status, and topoisomerase I pathway adaptation. | HER2 antigen loss/downregulation, payload efflux, and dose-limiting ILD/pneumonitis leading to discontinuation. | — |
Positioning Development positioning | Second TROP2 ADC to market; competes with Trodelvy on tolerability rather than novelty of target. | Leading efficacy in HER2 ADC class | — |
Technology Payload | DXd (exatecan derivative, topoisomerase I inhibitor) | DXd (topo-I inhibitor) | — |
Technology Linker | Tetrapeptide-based cleavable maleimide linker, DAR ~4 | Cleavable tetrapeptide | — |
Technology DAR | DAR 4 | — | — |
MoA Mechanism | Anti-TROP2 antibody delivers DXd intracellularly after lysosomal linker cleavage; topoisomerase I inhibition drives DNA damage, with membrane-permeable payload producing a bystander effect. | Fam-trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate: humanized anti-HER2 IgG1 linked via a cleavable tetrapeptide linker to DXd, a membrane-permeable topoisomerase I inhibitor. After binding HER2 on tumor cells, the conjugate is internalized; lysosomal proteases cleave the linker and release DXd, causing DNA damage and apoptosis. Released DXd can exert a bystander effect in neighboring cells. | CAR-T cell therapy for GAD65 antibody-mediated cerebellar ataxia |
MoA Biomarker | TROP2 expression is not a required companion diagnostic; quantitative continuous scoring (QCS) is investigational. | HER2 expression (IHC/ISH per indication); higher systemic exposure associated with greater ILD incidence (FDA label §12.2). | biomarkers exist to predict toxicity risk, underscoring the need for further research |
PK/PD Half-life | ADC ~6 days; released DXd cleared rapidly | ADC ~5.8 days; total antibody ~6.1 days; released DXd ~2.7 days (5.4 mg/kg q3w) | — |
PK/PD Species | Cynomolgus monkey, Mouse, PFS by BICR, ctDNA and TROP2 QCS exploratory | Minipig, Pig, Human, Tumor response (ORR, PFS), ILD incidence rises with exposure | Mouse |
PK/PD Animal (cat.) | Human, Mouse, NHP, In vitro | Human, In vitro | Human, Mouse |
PK/PD Experiment | pd | Pharmacokinetic | Pd |
PK/PD Biodistribution | — | Systemic exposure with tumor-selective HER2-mediated uptake | — |
Toxicology Species | Mouse, Rat, Hamster | Cynomolgus monkey, NHP, Rat, Minipig, Pig, Hamster, Human | Mouse |
Toxicology Animal (cat.) | — | NHP | Human, Mouse |
Toxicology Major finding | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. | ILD-like lung findings at high exposure | thrombocytopenia) but achieved a best response of morphologic leukemia-free state on day 14 foll |
Toxicology CRS | N/A | Minimal | Reported |
Toxicology NOAEL | — | 10 mg/kg | — |
Clinical Safety signal | Stomatitis, dry eye and keratitis, nausea, and alopecia. Interstitial lung disease is a class warning for DXd conjugates and requires prompt steroid intervention. | ILD-like lung findings at high exposure | thrombocytopenia) but achieved a best response of morphologic leukemia-free state on day 14 foll |
Clinical Selected reported efficacy | ORR 79% | ORR 79.7% | ORR 43.8% |
Clinical Reported ORR | 74% | 79.7% | 43.8% |
Clinical Reported PFS | 4.4 | NA | — |
Clinical Reported OS | 12.9 | NA | — |
Clinical Result source | ClinicalTrials.gov NCT04656652 | ClinicalTrials.gov NCT03529110 | ClinicalTrials.gov NCT02445248 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Clinical Trial ref | NCT04656652 | NCT03529110 | NCT02445248 |
Preclinical Animal (cat.) | Mouse, In vitro | Human, Mouse, In vitro | — |
추천 비교
추천 비교